- Home
- ALXO vs RDCM Comparison
ALXO vs RDCM Comparison
Compare ALXO & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | RDCM |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 170.6M |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ALXO | RDCM |
|---|---|---|
| Price | $1.99 | $10.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 941.1K | 189.6K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.50 |
| Revenue Next Year | N/A | $9.74 |
| P/E Ratio | ★ N/A | $16.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $9.40 |
| 52 Week High | $2.66 | $16.74 |
Technical Indicators
Market Signals| Indicator | ALXO | RDCM |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 33.68 |
| Support Level | $1.93 | $9.40 |
| Resistance Level | $2.21 | $13.19 |
| Average True Range (ATR) | 0.12 | 0.37 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 38.72 | 56.37 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.